Homepage Top Section2 Archives - Page 123 of 123 - Pharmaceutical Business review

Pharmaceutical Business review is using cookies

Continue Learn More

Close

Homepage Top Section2

- Drug Discovery
- Research & Development
August 27, 2018

JWP out-licenses atopic dermatitis drug JW1601 to LEO in $402m deal

By vbandhakavi

The agreement will not include South Korea where JWP will retain its exclusivity over the JW1601 drug, which was developed by one of its affiliates – C&C Research
Regulation
Approvals
August 23, 2018

FDA approves Dompé’s Oxervate to treat neurotrophic keratitis

By PBR Staff Writer

NK is a rare and progressive eye disease, which may result in corneal scarring and vision loss. The FDA has approved Oxervate eye drops for use in adults
Clinical Trials
Human Trials
August 22, 2018

Rexahn partners with Merck on combo study in TNBC

By PBR Staff Writer

The partnership will assess Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy in a phase 2 study in patients with metastatic triple negative breast cancer (TNBC). The trial has been